The COVID Boom: CBER Receives More INDs in One Quarter Than The Previous 30 Combined

 
• By Derrick Gingery

Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.

Hand grabbing rising line
CBER continued to see INDs for cell and gene therapies, in addition to COVID-19 countermeasures, in recent months. • Source: Alamy

More from United States

More from North America